The market's overwhelming 91.5% implied probability for no Hantavirus vaccine available in 2026 reflects the extended timelines inherent in vaccine development for this rodent-borne virus, which causes sporadic hantavirus pulmonary syndrome with no licensed product currently authorized by regulatory bodies. Authoritative surveillance data from agencies tracking emerging pathogens show limited case volumes and transmission rates that do not prioritize accelerated funding or large-scale trials, leaving most candidates in preclinical or early-phase testing with standard multi-year requirements for safety, efficacy, and manufacturing validation. While advances in platform technologies offer potential shortcuts, model projections and historical patterns for similar orthohantaviruses indicate realistic barriers to 2026 rollout; any unexpected Phase 3 success or emergency authorization could alter trajectories, though such shifts remain low-probability events pending new data releases.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日Hantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
$92,922 Vol.
$92,922 Vol.
2026/12/31
$92,922 Vol.
$92,922 Vol.
2026/12/31
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.The market's overwhelming 91.5% implied probability for no Hantavirus vaccine available in 2026 reflects the extended timelines inherent in vaccine development for this rodent-borne virus, which causes sporadic hantavirus pulmonary syndrome with no licensed product currently authorized by regulatory bodies. Authoritative surveillance data from agencies tracking emerging pathogens show limited case volumes and transmission rates that do not prioritize accelerated funding or large-scale trials, leaving most candidates in preclinical or early-phase testing with standard multi-year requirements for safety, efficacy, and manufacturing validation. While advances in platform technologies offer potential shortcuts, model projections and historical patterns for similar orthohantaviruses indicate realistic barriers to 2026 rollout; any unexpected Phase 3 success or emergency authorization could alter trajectories, though such shifts remain low-probability events pending new data releases.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
マーケット開始日： May 4, 2026, 10:39 AM ET
音量
$92,922終了日
2026/12/31マーケット開始日
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.The market's overwhelming 91.5% implied probability for no Hantavirus vaccine available in 2026 reflects the extended timelines inherent in vaccine development for this rodent-borne virus, which causes sporadic hantavirus pulmonary syndrome with no licensed product currently authorized by regulatory bodies. Authoritative surveillance data from agencies tracking emerging pathogens show limited case volumes and transmission rates that do not prioritize accelerated funding or large-scale trials, leaving most candidates in preclinical or early-phase testing with standard multi-year requirements for safety, efficacy, and manufacturing validation. While advances in platform technologies offer potential shortcuts, model projections and historical patterns for similar orthohantaviruses indicate realistic barriers to 2026 rollout; any unexpected Phase 3 success or emergency authorization could alter trajectories, though such shifts remain low-probability events pending new data releases.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
音量
$92,922終了日
2026/12/31マーケット開始日
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...The market's overwhelming 91.5% implied probability for no Hantavirus vaccine available in 2026 reflects the extended timelines inherent in vaccine development for this rodent-borne virus, which causes sporadic hantavirus pulmonary syndrome with no licensed product currently authorized by regulatory bodies. Authoritative surveillance data from agencies tracking emerging pathogens show limited case volumes and transmission rates that do not prioritize accelerated funding or large-scale trials, leaving most candidates in preclinical or early-phase testing with standard multi-year requirements for safety, efficacy, and manufacturing validation. While advances in platform technologies offer potential shortcuts, model projections and historical patterns for similar orthohantaviruses indicate realistic barriers to 2026 rollout; any unexpected Phase 3 success or emergency authorization could alter trajectories, though such shifts remain low-probability events pending new data releases.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問